Navigation Links
Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
Date:10/30/2007

eriod, an increase of 4%.

General and administrative (G&A) expenses in the third quarter of 2007 were $11.4 million, compared to $12.7 million in the prior year period, a decrease of 10%. In the third quarter of 2006, the Company paid its outside litigation counsel $2.0 million in connection with the Company's successful settlement of the Bayer patent litigation. For the first nine months of 2007, G&A expenses were $34.7 million, compared to $34.1 million in the prior year period, an increase of 2%.

Gen-Probe continues to have a strong balance sheet. As of September 30, 2007, the Company had $395.1 million of cash, cash equivalents and short-term investments, and no debt. In the first nine months of 2007, Gen-Probe generated net cash of $71.2 million from its operating activities, higher than the Company's year-to-date net income of $65.7 million.

Updated 2007 Financial Guidance

"Based on our strong performance in the third quarter, we are raising our full-year 2007 revenue and EPS guidance," said Herm Rosenman, the Company's senior vice president of finance and chief financial officer.

For the full year 2007, Gen-Probe now expects:

-- Total revenues of $400 million to $402 million.

-- Product gross margins approximating 67% to 68% of product sales.

-- R&D expenses approximating 24% to 25% of total revenues.

-- Marketing and sales expenses approximating 9% to 10% of total

revenues.

-- G&A expenses approximating 11% to 12% of total revenues.

-- A reported tax rate of approximately 24.5%, including one-time

benefits associated with the completion of tax audits and adjustments.

-- EPS of between $1.50 and $1.52, based on approximately 54 million to

55 million fully diluted shares outstanding for the year.

Recent Events

-- John C. Martin Elected to Board of Directors. On September 20,

Gen-Probe announced that John C. Martin, Ph.D., pre
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fertility Associates ... Donor Egg Bank USA , a network of more ... Through this partnership, patients have fast access to a ... vitro fertilization, IVF . Fertility Associates of Memphis is ... this fertility treatment option. , Dr. William Kutteh ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... Boehringer Ingelheim today,announced that the company ... as the,world,s most respected biopharmaceutical employer. Science,s ... polls employees in the biotechnology,biopharmaceutical, pharmaceutical, and ... asked to rate companies based on 23 ...
... featured in oral presentation ... TSX Exchange Symbol: ... is pleased to announce that tomorrow it is making,an oral ... at the International Atherosclerosis Society (IAS),Workshop on HDL. The presentation ...
... New sol-gel inks developed by researchers at the University ... three-dimensional structures of metal oxides with nanoscale features. , ... nanoscale opens a new avenue to functional devices. Potential ... The researchers describe the new inks in a paper ...
Cached Biology Technology:Boehringer Ingelheim Receives Top Honor as World's Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 2Boehringer Ingelheim Receives Top Honor as World's Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 3Resverlogix is Presenting at IAS HDL Workshop 2Sol-gel inks produce complex shapes with nanoscale features 2
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Orleans, LA Research led by Wayne L. Backes, PhD, ... Health Sciences Center New Orleans School of Medicine, has found ... present in an individual, but also how they interact, and ... safely eliminated from the body or is converted into a ...
... Pa. , March 17 Orbel,s ... design your own PCB shield. Visit the BLS section ... from a wide variety of surface mount or ... The easy-to-use application lets you enter shield dimensions, ...
... A new study involving scientists from 13 different ... protection offers one of the most effective, practical, ... study, "Indigenous Lands, Protected Areas, and Slowing Climate ... a peer-reviewed scientific journal, and makes specific recommendations ...
Cached Biology News:LSUHSC research increases understanding of drug metabolism 2Orbel Introduces the Board Shielding Wizard 2Study highlights forest protected areas as a critical strategy for slowing climate change 2
... through 63 ligand binding ... a broad therapeutic range. ... many non human tissue ... assays. Used to ...
...
... Sequencer 20 System revolutionizes DNA sequencing, delivering ... The Genome Sequencer 20 System includes: ... and consumables for library construction, amplification, and ... de novo assembly The ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: